XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents segment revenue and significant segment expenses (in thousands) for the three and nine months ended September 30, 2025 and 2024:
THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,
2025202420252024
REVENUE:
Total segment revenue14,262 388 243,676 508 
LESS:
KER-065 program expenses(1,345)(4,935)(4,293)(12,225)
Elritercept program expenses(3,341)(13,576)(37,872)(33,161)
Cibotercept program expenses(1,218)(8,618)(11,185)(20,820)
Preclinical & development expenses(1,700)(4,206)(5,425)(10,322)
Compensation costs (excluding stock based compensation)(9,568)(11,830)(37,187)(35,186)
Stock-based compensation(3,986)(8,817)(21,391)(25,672)
Depreciation expense(395)(315)(1,109)(897)
Other segment items2(8,346)(6,840)(29,187)(20,529)
Dividend income6,933 5,793 20,845 16,977 
Income tax (provision) benefit1,424 — (6,397)— 
Net income (loss)(7,280)(52,956)110,475 (141,327)